The Russian Sputnik V vaccine is 91.6% effective at preventing symptomatic Covid-19, according to preliminary results from a phase 3 trial published in The Lancet on Tuesday, placing it in a similar league to the mRNA vaccines developed by Pfizer-BioNtech and Moderna.

The publication is important because scientists have previously expressed concern about Russia’s decision to start wide-scale vaccination with Sputnik V before releasing phase 3 trial data for public scrutiny, and the haste with which more than a dozen other nations have approved the shot...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now